Top US Court Is Asked To Review Inter Partes Reviews
Standards for determining obviousness via inter partes patent reviews, as well as procedures for affirming such determinations on appeal, must be reviewed by the US Supreme Court, two originators argue in their dispute with Akorn over Durezol difluprednate eye drops.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.